ECSP20074392A - ESTIMULADOR DE TREG SELECTIVO RUR20kD-IL-2 Y COMPOSICIONES RELACIONADAS - Google Patents

ESTIMULADOR DE TREG SELECTIVO RUR20kD-IL-2 Y COMPOSICIONES RELACIONADAS

Info

Publication number
ECSP20074392A
ECSP20074392A ECSENADI202074392A ECDI202074392A ECSP20074392A EC SP20074392 A ECSP20074392 A EC SP20074392A EC SENADI202074392 A ECSENADI202074392 A EC SENADI202074392A EC DI202074392 A ECDI202074392 A EC DI202074392A EC SP20074392 A ECSP20074392 A EC SP20074392A
Authority
EC
Ecuador
Prior art keywords
rur20kd
related compositions
compositions
selective treg
treg stimulator
Prior art date
Application number
ECSENADI202074392A
Other languages
English (en)
Inventor
Peter Benedict Kirk
Jonathan Zalevsky
John L Langowski
Original Assignee
Nektar Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nektar Therapeutics filed Critical Nektar Therapeutics
Publication of ECSP20074392A publication Critical patent/ECSP20074392A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente divulgación proporciona composiciones de estimulador de Treg selectivo, que incluyen RUR20kD-IL-2 y composiciones relacionadas, y métodos de uso de estas composiciones, por ejemplo, para tratar enfermedades autoinmunitarias y/u otras afecciones que responden al tratamiento que es eficaz para proporcionar un aumento de las cantidades y la activación de los linfocitos T reguladores sobre los linfocitos T efectores.
ECSENADI202074392A 2018-05-21 2020-11-20 ESTIMULADOR DE TREG SELECTIVO RUR20kD-IL-2 Y COMPOSICIONES RELACIONADAS ECSP20074392A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862674244P 2018-05-21 2018-05-21

Publications (1)

Publication Number Publication Date
ECSP20074392A true ECSP20074392A (es) 2021-03-31

Family

ID=67002369

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202074392A ECSP20074392A (es) 2018-05-21 2020-11-20 ESTIMULADOR DE TREG SELECTIVO RUR20kD-IL-2 Y COMPOSICIONES RELACIONADAS

Country Status (20)

Country Link
US (1) US20210205413A1 (es)
EP (1) EP3796940A1 (es)
JP (2) JP7235772B2 (es)
KR (1) KR20210002577A (es)
CN (1) CN112399859A (es)
AU (2) AU2019274409B2 (es)
BR (1) BR112020021564A2 (es)
CA (1) CA3100204A1 (es)
CL (1) CL2020003008A1 (es)
CO (1) CO2020014510A2 (es)
CR (1) CR20200546A (es)
DO (1) DOP2020000212A (es)
EA (1) EA202092489A1 (es)
EC (1) ECSP20074392A (es)
IL (1) IL278528B1 (es)
JO (1) JOP20200290A1 (es)
PE (1) PE20211307A1 (es)
PH (1) PH12020551976A1 (es)
SG (1) SG11202011242SA (es)
WO (1) WO2019226538A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115315436A (zh) * 2020-01-10 2022-11-08 明峰治疗股份公司 修饰的il-2多肽及其用途
US20230102464A1 (en) * 2020-01-15 2023-03-30 Jenkem Technology Co., Ltd. (Tianjin) Method for preparing pegylated biomolecule with controllable binding sites
CN113121670B (zh) * 2020-01-15 2022-11-22 天津键凯科技有限公司 二取代peg化白细胞介素2及其制备方法、应用
US20230272001A1 (en) * 2020-05-22 2023-08-31 Merck Sharp & Dohme Llc Novel processes for preparing conjugates of the il-2 protein
TW202228784A (zh) 2020-09-23 2022-08-01 奧地利商艾柏力維亞生技有限公司 用以於一患者中螯合非預期的抗ｐｅｇ抗體的化合物
US20230414720A1 (en) * 2020-11-23 2023-12-28 University Of Florida Research Foundation, Incorporated Use of insulin-like growth factors with gamma-chain cytokines to induce homeostatic proliferation of lymphocytes
WO2023114833A1 (en) 2021-12-14 2023-06-22 Eli Lilly And Company Dosing regimens for selective treg stimulator rur20kd-il-2 and related compositions

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4401756A (en) 1981-04-14 1983-08-30 Immunex Corporation Process for preparing human interleukin 2
US4569790A (en) 1984-03-28 1986-02-11 Cetus Corporation Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions
US5116943A (en) 1985-01-18 1992-05-26 Cetus Corporation Oxidation-resistant muteins of Il-2 and other protein
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US5153310A (en) 1989-02-28 1992-10-06 Du Pont Merck Pharmaceutical Company Il-2 analogs containing n-linked glycosylation sites
US5635597A (en) 1994-05-27 1997-06-03 Affymax Technologies, N.V. Peptides that bind IL-2 receptors
US6168785B1 (en) 1998-07-16 2001-01-02 Institut Pasteur Biological applications of new peptides of IL-2 and derivatives and use as therapeutic agents
FR2826365B1 (fr) 2001-06-20 2003-09-26 Oreal Compositions cosmetiques photoprotectrices contenant des derives amides, sulfonamides ou carbamates aromatiques d'acrylonitrile et nouveaux derives amides, sulfonamides ou carbamates d'acrylonitrile
EP3593820A1 (en) 2003-05-23 2020-01-15 Nektar Therapeutics Peg derivatives containing two peg chains
WO2005007121A2 (en) 2003-07-18 2005-01-27 Massachusetts Institute Of Technology Mutant interleukin-2(il-2) polypeptides
US7567215B1 (en) 2007-10-23 2009-07-28 The United States Of America As Represented By The Secretary Of The Navy Portable and inflatable antenna device
KR102591732B1 (ko) * 2010-11-12 2023-10-19 넥타르 테라퓨틱스 Ｉｌ-2 부분 및 중합체의 접합체
CN109432407A (zh) * 2011-03-11 2019-03-08 公共事业救济局-巴黎医院 低剂量il-2用于治疗自身免疫相关病症或炎性病症的应用
US10898576B2 (en) * 2016-03-16 2021-01-26 Yanhui Xie Glucocorticoid combined with polyethylene glycol-modified interleukin 2 for treating respiratory disease

Also Published As

Publication number Publication date
CA3100204A1 (en) 2019-11-28
PE20211307A1 (es) 2021-07-20
JP7235772B2 (ja) 2023-03-08
IL278528A (es) 2021-01-31
CR20200546A (es) 2021-05-18
JP2023052053A (ja) 2023-04-11
PH12020551976A1 (en) 2021-09-13
SG11202011242SA (en) 2020-12-30
AU2019274409A1 (en) 2020-11-12
CN112399859A (zh) 2021-02-23
US20210205413A1 (en) 2021-07-08
WO2019226538A1 (en) 2019-11-28
EP3796940A1 (en) 2021-03-31
AU2019274409B2 (en) 2022-07-14
AU2022246440A1 (en) 2022-11-03
DOP2020000212A (es) 2021-03-15
IL278528B1 (en) 2024-06-01
CO2020014510A2 (es) 2021-03-08
BR112020021564A2 (pt) 2021-03-02
JOP20200290A1 (ar) 2020-11-15
EA202092489A1 (ru) 2021-03-16
JP2021523922A (ja) 2021-09-09
CL2020003008A1 (es) 2021-07-30
KR20210002577A (ko) 2021-01-08

Similar Documents

Publication Publication Date Title
CO2020014510A2 (es) Estimulador de treg selectivo rur20kd-il-2 y composiciones relacionadas
CL2019000935A1 (es) Composición farmacéutica, métodos para tratamiento y usos de la misma.
CL2019001874A1 (es) Inhibidores de tgfß1 isoforma-específicos contexto-permisivos y uso de los mismos.
CL2018003213A1 (es) Inhibidores enzimáticos.
ES2692773T3 (es) Tratamientos para la fibrosis
EA201790195A1 (ru) Способы лечения рака с применением ингибиторов tigit и противораковых агентов
CO2019006902A2 (es) Anticuerpos humanos a la toxina hemolisina a de s. aureus
UY36741A (es) Compuesto de esteroide c-20, sus composiciones y usos para tratar la lesión cerebral traumática (tbi), que incluye las conmociones cerebrales
CO2021004141A2 (es) Moduladores de la expresión de pnpla3
BR112019005944A2 (pt) anticorpos que se ligam à interleucina 2 e usos dos mesmos
CL2020003447A1 (es) Composiciones y métodos para el tratamiento de enfermedades o condiciones relacionadas con inflamasomas
AR113618A1 (es) Péptidos antimicrobianos y métodos para usarlos
BR112017007813A2 (pt) composições oftalmológicas, método de prevenção, redução ou tratamento de transtornos causados por olhos secos e uso de ciclosporina e trealose
CL2018003214A1 (es) Composiciones cosméticas prebióticas y uso de las composiciones cosméticas prebióticas
BR112019021300A8 (pt) Composições de fragrâncias e produtos com efeitos de melhora do humor
NI202000085A (es) Moduladores de la expresión de apol1
BR112018005855A2 (pt) tratamento de doenças neurodegenerativas
CO2019011265A2 (es) Moduladores de la expresión de pcsk9
CL2021001246A1 (es) Moduladores de expresión irf5.
PE20210109A1 (es) Moduladores de la expresion de irf4
CO2022009433A2 (es) Uso de isatuximab para el tratamiento del mieloma múltiple recidivante y/o refractario
BR112018010596A2 (pt) anticorpos para cgrp e usos dos mesmos
CL2021000928A1 (es) Composiciones y métodos para la estimulación ovárica controlada
AR120038A1 (es) Anticuerpos anti-nrp1a y sus usos para tratar enfermedades oculares
MX2021004819A (es) Composiciones y metodos para tratar lesiones cerebrales.